Get to know our clinical trials
Clinical trial with BAY 2927088 tablets for in patients who have a solid tumor with human epidermal growth factor receptor 2 mutations
THE MAIN OBJECTIVE IS TO EVALUATE THE EFFICACY OF BAY 2927088 IN OBJECTIVE RESPONSE RATE (ORR) ASSESSED BY BLINDED INDEPENDENT CENTRALIZED REVIEW (BICR).
Technical Summary
- PHASE 2, OPEN-LABEL, BASKET CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF THE ORALLY ADMINISTERED REVERSIBLE TYROSINE KINASE INHIBITOR BAY 2927088 IN PATIENTS WITH METASTATIC OR UNRESECTABLE SOLID TUMORS WITH HER2 ACTIVATING MUTATIONS.
- Code EudraCT: 2024-517419-62-00
- Protocol number: BAY 2927088 / 22752
- Promoter: Bayer Hispania S.L
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.